Effect and Safety of Tamsulosin, the Prostate Specific α1-Blocker, in the Treatment of BPH (Benign Prostatic Hyperplasia)
K. Kawabe
Abstract
K. Kawabe
Abstract
Clinical trials of tamsulosin demonstrate that it is an effective treatment modality for the symptoms associated with BPH, and it has practically no effect on blood pressure at a dose of 0.2 mg. This is probably due to its selective affinity for the prostate, which may be due to the strong affinity of tamsulosin for the α 1a -receptor subtype.
OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Clinical trials of tamsulosin demonstrate that it is an effective treatment modality for the symptoms associated with BPH, and it has practically no effect on blood pressure at a dose of 0.2 mg. This is probably due to its selective affinity for the prostate, which may be due to the strong affinity of tamsulosin for the α 1a -receptor subtype.
Key concepts: Tamsulosin, Urology, Hyperplasia, Medicine, Prostate, Benign prostatic hyperplasia (BPH), Alfuzosin, Internal medicine